Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Systemic Inflammation and Kidney Stone Disease in Autosomal Dominant Polycystic Kidney Disease
You, Zhiying , Brosnahan, Godela , Chapman, Arlene B., Chonchol, Michel , Gitomer, Berenice Y , Wang, Wei , Hopp, Katharina , Nowak, Kristen L. , Perrone, Ronald D. , Torres, Vicente E. , Yu, Alan S.L.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 159-159

10.1681/asn.20223311s1159b Get It

Antibiotic Use and Kidney Stone Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
You, Zhiying , Brosnahan, Godela , Jovanovich, Anna, Chapman, Arlene B., Chonchol, Michel , Gitomer, Berenice Y , Wang, Wei , Hopp, Katharina , Nowak, Kristen L. , Jovanovich, Anna J. , Perrone, Ronald D. , Torres, Vicente E. , Yu, Alan S.L.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 159-159

10.1681/asn.20223311s1159a Get It

Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease
Thao, Ka, LaBranche, Timothy P. , Palmer, Michael R., McKnight, Stanley, Hoeflich, Klaus P. , Schalm, Stefanie S. , Wang, Xiaofang , Li, Jiang , Sussman, Caroline R. , Palmer, Michael R., Harris, Peter C. , Torres, Vicente E.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 393-393

10.1681/asn.20213210s1393b Get It

Weight Loss to Slow Cyst Growth in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Kline, Timothy L. , Wang, Wei , You, Zhiying , Bing, Kristen , Poudyal, Bhavya , Chonchol, Michel , Nowak, Kristen L. , Catenacci, Victoria A. , Steele, Cortney , Gitomer, Berenice Y

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 404-404

10.1681/asn.20213210s1404a Get It

Pharmacological Activation of Long-Form PDE4 Enzymes Suppresses Disease Progression in Pkd1RC/RC and Pkd1 Knockout (iKspCrePkd-1lox,lox) Mouse Models of ADPKD
Henderson, David , Adam, Julia M., Adams, David R. , Rowley, Adele, Wang, Xiaofang , Li, Jiang , Houslay, Miles D. , Harris, Peter C. , Torres, Vicente E.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 401-402

10.1681/asn.20213210s1401d Get It

A Post Hoc Analysis of Tolvaptan (TOL) Efficacy and Safety in Slowing Rate of Renal Function Decline in Subjects with Very Late-Stage Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Gansevoort, Ron T. , Chapman, Arlene B., Ouyang, John , Lee, Jennifer , Japes, Hina, Torres, Vicente E. , Perrone, Ronald D. , Wang, Tao

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 490-490

10.1681/asn.20203110s1490c Get It

Overweight and Obesity Are Predictors of Pain in the HALT-PKD Studies
You, Zhiying , Brosnahan, Godela , Miskulin, Dana C. , Steinman, Theodore I., Braun, William E. , Chapman, Arlene B., Chonchol, Michel , Study, HALT-PKD, Wang, Wei Qiang , Gitomer, Berenice Y , Harris, Peter C. , Torres, Vicente E. , Abebe, Kaleab Z , Yu, Alan S.L. , Perrone, Ronald D. , Nowak, Kristen L. , Study, HALT-PKD

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 500-500

10.1681/asn.20203110s1500a Get It

Bibliometric analysis and evaluation of publications on non- Helicobacter pylori helicobacters from 1993 to 2023
Wang, Menghui, Fang, Hui, Zhou, Chulin , Ouyang, Yaobin, Yu, Chenfeng, Zhang, Yang, Zhu, Xiaoyi, Xie, Chuan, Deng, Qiliang, Ouyang, Yaobin , Xie, Chuan

Mayo Clinic

Future Microbiology | May 16, 2024 | Volume: 19 | Issue: 10 | Pages: 889-901

10.2217/fmb-2024-0034 | PMID 38700283 Get It

Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
Haddad, Tufia C. , Suman, Vera J. , Sideras, Kostandinos , Northfelt, Donald W. , Ernst, Brenda , O’Sullivan, Ciara C. , Singh, Ravinder J. , Desta, Zeruesenay , Peethambaram, Prema P. , Hobday, Timothy J. , Chumsri, Saranya , Leon‐Ferre, Roberto A. , Ruddy, Kathryn J. , Taraba, Jodi L. , Goodnature, Barbara, Wang, Liewei , Giridhar, Karthik V , Sideras, Kostandinos , Northfelt, Donald , Ernst, Brenda , O'Sullivan, Ciara Catherine , Singh, Ravinder J , Desta, Zeruesenay , Peethambaram, Prema P , Hobday, Timothy J , Chumsri, Saranya , Leon-Ferre, Roberto , Ruddy, Kathryn J , Yadav, Siddhartha , Taraba, Jodi L , Goodnature, Barbara , Goetz, Matthew P , Wang, Liewei , Ingle, J , Suman, Vera , Giridhar, Karthik V. , Yadav, Siddhartha , Goetz, Matthew P. , Ingle, James N.

Mayo Clinic

Clinical Cancer Research | May 16, 2024 | Volume: 30 | Issue: 15 | Pages: 3147-3156

10.1158/1078-0432.ccr-24-0341 | PMID 38752717 Get It

Abstract Purpose: We previously reported that postmenopausal women with estrogen receptor-α–positive breast cancer receiving adjuvant anastrozole 1 mg/day (ANA1) with estrone (E1) ≥1.3 pg/mL and estradiol (E2) ≥0.5 pg/mL [inadequate estrogen suppression (IES)] had a threefold increased risk of a breast cancer event. The objective of this study was to determine if increasing anastrozole to 10 mg/day (ANA10) could result in adequate estrogen suppression (AES: E1 <1.3 pg/mL and/or E2 <0.5 pg/mL) among those with IES on ANA1. Patients and Methods: Postmenopausal women with estrogen receptor-α–positive breast cancer planning to receive adjuvant ANA1 were eligible. E1 and E2 were assessed pre- and post-8 to 10 weeks of ANA1. Those with IES were switched to 8- to 10-week cycles of ANA10 followed by letrozole 2.5 mg/day. E1 and E2 were assessed after each cycle. Anastrozole concentrations were measured post-ANA1 and post-ANA10. Primary analyses included patients who documented taking at least 80% of the planned treatment (adherent cohort). Results: In total, 132 (84.6%) of 156 eligible patients were ANA1 adherent. IES occurred in 40 (30.3%) adherent patients. Twenty-five (78.1%) of 32 patients who began ANA10 were adherent, and AES was achieved in 19 (76.0%; 90% confidence interval, 58.1%–89.0%) patients. Anastrozole concentrations post-ANA1 and post-ANA10 did not differ by estrogen suppression status among adherent patients. AES was maintained/attained in 21 (91.3%) of 23 letrozole-adherent patients. Conclusions: Approximately 30% of ANA1-adherent patients had IES. Among those who switched to ANA10 and were adherent, 76% had AES. Further studies are required to validate emerging data that ANA1 results in IES for some patients and to determine the clinical benefit of switching to ANA10 or an alternative aromatase inhibitor.